Authors
Margaret M Redfield, Horng H Chen, Barry A Borlaug, Marc J Semigran, Kerry L Lee, Gregory Lewis, Martin M LeWinter, Jean L Rouleau, David A Bull, Douglas L Mann, Anita Deswal, Lynne W Stevenson, Michael M Givertz, Elizabeth O Ofili, Christopher M O’Connor, G Michael Felker, Steven R Goldsmith, Bradley A Bart, Steven E McNulty, Jenny C Ibarra, Grace Lin, Jae K Oh, Manesh R Patel, Raymond J Kim, Russell P Tracy, Eric J Velazquez, Kevin J Anstrom, Adrian F Hernandez, Alice M Mascette, Eugene Braunwald
Publication date
2013/3/27
Journal
Jama
Volume
309
Issue
12
Pages
1268-1277
Publisher
American Medical Association
Description
Importance
Studies in experimental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascular function and thus exercise capacity in heart failure with preserved ejection fraction (HFPEF).
Objective
To determine the effect of the phosphodiesterase-5 inhibitor sildenafil compared with placebo on exercise capacity and clinical status in HFPEF.
Design
Multicenter, double-blind, placebo-controlled, parallel-group, randomized clinical trial of 216 stable outpatients with HF, ejection fraction ≥50%, elevated N-terminal brain-type natriuretic peptide or elevated invasively measured filling pressures, and reduced exercise capacity. Participants were randomized from October 2008 through February 2012 at 26 centers in North America. Follow-up was through August 30, 2012.
Interventions
Sildenafil (n = 113) or placebo (n = 103) administered orally at 20 mg, 3 times daily for 12 weeks …
Total citations
Scholar articles
MM Redfield, HH Chen, BA Borlaug, MJ Semigran… - Jama, 2013